Howard Levy

All filings by Howard Levy on record concern Gyre Therapeutics, Inc., in the capacity of senior executive. We count 13 filings; the first trade dates from 3 May 2018 and the latest from 9 August 2021.

Both buying and selling appear: 4 purchases worth €25k, against 1 sale worth €1,680. Netting one side against the other leaves €23k of net buying. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 2 share grants and 5 option exercises. In 2021 alone, the filings show 2 purchases and no sales.

In size, the median ticket on the buying side is €6,955. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 11 August 2021, reports an open-market purchase of €1,971 in Gyre Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.